磷脂酰聚糖蛋白 3 抗体：肝癌的一个新治疗靶点。
Glypican-3 antibodies: a new therapeutic target for liver cancer.
机构信息
Antibody Therapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Antibody Therapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
FEBS Lett. 2014 Jan 21;588(2):377-82. doi: 10.1016/j.febslet.2013.10.002. Epub 2013 Oct 15.
Glypican-3 (GPC3) is an emerging therapeutic target in hepatocellular carcinoma (HCC), even though the biological function of GPC3 remains elusive. Currently human (MDX-1414 and HN3) and humanized mouse (GC33 and YP7) antibodies that target GPC3 for HCC treatment are under different stages of preclinical or clinical development. Humanized mouse antibody GC33 is being evaluated in a phase II clinical trial. Human antibodies MDX-1414 and HN3 are under different stages of preclinical evaluation. Here, we summarize current evidence for GPC3 as a new target in liver cancer, discuss both its oncogenic function and its mode of actions for current antibodies, and evaluate potential challenges for GPC3-targeted anti-cancer therapies.
磷脂酰聚糖-3（GPC3）是肝细胞癌（HCC）的一个新兴治疗靶点，尽管其生物学功能仍不清楚。目前有针对 GPC3 的用于 HCC 治疗的人源化（MDX-1414 和 HN3）和人源（GC33 和 YP7）抗体处于不同的临床前或临床开发阶段。人源化鼠抗体 GC33 正在进行 II 期临床试验评估。人源抗体 MDX-1414 和 HN3 处于不同的临床前评估阶段。在这里，我们总结了 GPC3 作为肝癌新靶点的现有证据，讨论了其致癌功能及其对现有抗体的作用机制，并评估了针对 GPC3 的抗癌治疗的潜在挑战。
Zotero 插件